{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"97.5","upperLimit":"99.8","value":"99.4"},{"groupId":"OG001","lowerLimit":"91.2","upperLimit":"96.3","value":"94.3"}]}],"title":"OS rate at 2 years (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.3","upperLimit":"97.1","value":"95.3"},{"groupId":"OG001","lowerLimit":"84.9","upperLimit":"91.8","value":"88.8"}]}],"title":"OS rate at 3 years (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.3","upperLimit":"90.9","value":"87.6"},{"groupId":"OG001","lowerLimit":"72.7","upperLimit":"81.9","value":"77.7"}]}],"title":"OS rate at 5 years (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"343"}],"units":"Participants"}],"description":"Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken once daily","id":"OG000","title":"AZD9291 80mg Tablet"},{"description":"Taken once daily","id":"OG001","title":"Placebo Tablet"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) stage IB-IIIA patients","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.","title":"Overall Survival Rate at 2, 3 and 5 Years","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}